D3 Bio

Focus: D3 Bio is a Series B oncology and immunology-focused biotech company headquartered in Wuxi, China, developing small molecule therapies targeting MAPK pathway and KRAS mutations in advanced solid tumors.

Oncology Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Total Funding

$200M

Open Jobs

About D3 Bio

AI assessmentNot Hiring

No open roles listed right now. Follow D3 Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

D3L-001

HER-2 Positive Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT05957536A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

Phase 1

Help build intelligence for D3 Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage exposure to validated oncology targets (KRAS, MAPK pathway) with multiple clinical programs in parallel
Opportunity to build from ground level at a Series B company with potential for significant equity upside before exit
Focus on high-unmet-need indications (advanced solid tumors) in oncology, a therapeutically rewarding space

Watch Out For

Zero active job openings listed, suggesting minimal near-term hiring or possible contraction
Pre-revenue stage with no disclosed funding amount creates cash runway uncertainty and restructuring risk
Lack of published data, public financials, and limited transparency makes company evaluation difficult for risk assessment

Generated by Claude from D3 Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

D3S-003

KRAS P.G12D

Phase 1

Clinical Trials (1)

NCT07456046A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

Phase 1

D3S-001

Healthy Adult Volunteers

Phase 1

Clinical Trials (1)

NCT07093398A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants

Phase 1

D3S-002

Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1/2

Clinical Trials (1)

NCT05886920A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1/2

D3S-001

KRAS P.G12C

Phase 1/2

Clinical Trials (1)

NCT05410145A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Phase 1/2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline